Navigation Links
Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market
Date:10/6/2010

d renal disease.

Use caution when prescribing CAMBIA with drugs known to be hepatotoxic (eg, acetaminophen, certain antibiotics, antiepileptics). Warn patients to avoid acetaminophen containing products while taking CAMBIA. The liver metabolizes almost 100% of diclofenac, and there is insufficient information to support dosing recommendations in patients with hepatic insufficiency. Hepatic effects range from transaminase elevations to liver failure. Discontinue CAMBIA immediately if abnormal liver tests persist or worsen.

NSAIDs can lead to new onset or worsening of preexisting hypertension. Monitor blood pressure closely during therapy. Patients taking ACE inhibitors, thiazides, or loop diuretics may have impaired response to these therapies when taking NSAIDs. Note that fluid retention and edema have been observed in some patients taking NSAIDs. Use CAMBIA with caution in patients with fluid retention or heart failure.

Using CAMBIA with other NSAIDs (eg, aspirin) or with anticoagulants (eg, warfarin) is not advised due to increased risk of serious adverse events, such as GI bleeding. Use with caution in patients with a history of ulcers or GI bleeding. Anemia may occur in patients on NSAIDs. In patients on long-term therapy, check hemoglobin or hematocrit upon any sign or symptom of anemia or blood loss.

NSAIDs, including CAMBIA, can cause serious skin reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which can be fatal. Discontinue use immediately if rash or other signs of local skin reaction occur.

CAMBIA can harm fetuses. Starting at 30 weeks' gestation, pregnant women should avoid CAMBIA and other NSAIDs as premature closure of the ductus arteriosus in the fetus may occur. Use with caution in nursing mothers as it is not known if diclofenac is excreted in human milk.

The most common adverse events in clinical trials with CAMBIA were nausea and dizziness.


'/>"/>
SOURCE Nautilus Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. US WorldMeds Acquires Solstice Neurosciences
2. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
3. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
4. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
5. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
6. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
7. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
8. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. DMC Sinai-Grace Selects Loopback Communications Readmission Reduction™ Services
11. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... This BCC Research report discusses the medical device technologies ... and size, and opportunities for different devices and regions. It ... analysis in the report focuses on technological trends in recent ... and Japan . ... global medical device technologies market. - Analyze market structure, including ...
(Date:9/18/2014)... Pa. , Sept. 18, 2014  Iliad Neurosciences, ... approaches to diagnosing and treating Autism Spectrum Disorders (ASD) ... License Agreement with The Research Foundation for The State ... Iliad will provide a new biomarker to identify an ... susceptibility to ASD. This biomarker is expected to be ...
(Date:9/18/2014)... 2014 Pharma IQ, ... incredibly successful Serialisation Countdown calendar to cover the years ... pharmaserialisation.com shows the serialisation requirements around the ... coming into force. For companies dealing with ... "if", but "when" they will have to comply with ...
Breaking Medicine Technology:Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2
... Sept. 9, 2011 Nektar Therapeutics (Nasdaq: ... company,s Phase 2 clinical study of NKTR-102 in patients ... 2011 Breast Cancer Symposium in San Francisco, California.  NKTR-102 ... proprietary polymer conjugate technology, and is being developed in ...
... The Advanced Wound Management division of Smith & Nephew ... from 11 studies on a range of products and therapies ... and RENASYS* wound care portfolio. The data demonstrate advanced ... wound care products. Results of the studies are being presented ...
Cached Medicine Technology:Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 2Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 3Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 4Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 5Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 6Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 2Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 3Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 4
(Date:9/19/2014)... (PRWEB) September 19, 2014 There are thousands ... for companionship and intimacy, and there are thousands of younger ... experienced, mature woman. SeekingCougar.com now provides the world's ... dating website caters to older women, and the younger men ... and convenient way for these people to meet each other ...
(Date:9/18/2014)... 19, 2014 When Mary Ann Thompson and Mathieu ... who live in Bali, Indonesia with their son, Isaac, said there ... two met at Mercy College in 2001 when Thompson was an ... was a graduate student at the time, was French and so ... and migrated to the United States when she was 7 years ...
(Date:9/18/2014)... Toronto, ON (PRWEB) September 18, 2014 ... Facial Plastic Surgeon with the American Academy of Facial ... University of Toronto in the Division of Facial Plastic ... his work in facial plastic surgery. , Dr. ... and foremost, he will be presenting on injection techniques ...
(Date:9/18/2014)... (HealthDay News) -- Rising temperatures in the Atlantic Ocean ... shallow waters that are becoming warmer, an expansion that ... report. A study of 40 species along the ... by the invasive and poisonous lionfish, according to researchers ... the University of North Carolina-Wilmington, who published their findings ...
(Date:9/18/2014)... It’s been just a few short weeks ... bunion splint to website visitors, but already the response has ... absolutely delighted. It is perfect and I find it sooo ... THANK YOU FOR LISTENING!!!" Another user compared the original ... used to slip to the end of my toe. Now ...
Breaking Medicine News(10 mins):Health News:Dating Site "SeekingCougar.com" Now Offering Tips for Younger Men Seeking Older Women 2Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3
... WEDNESDAY, March 9 (HealthDay News) -- A newly identified toxin ... treat pain and disease in humans, scientists report. Spider ... control the flow of ions across cell membranes and play ... diseases. In their research on the venom of the ...
... 9 (HealthDay News) -- What difference does it make if ... millennia? A lot, as it turns out. Losing a few ... differently than those of other mammals. It may also be the ... some other animals, including chimpanzees and mice. It appears that ...
... polite act shows respect. But a new study of a ... a more practical, though unconscious, shared motivation: to reduce the ... and David A. Rosenbaum of Pennsylvania State University, is the ... altruism and motor control. It is to be published in ...
... clear and watery substance that bathes the brain and ... previously realized. Howard Hughes Medical Institute investigator Christopher ... Zappaterra, and their colleagues have discovered that cerebrospinal fluid ... dramatically with age. In the lab, CSF by itself ...
... News) -- Certain types of medical errors are 46 ... than bottom-ranked hospitals, according to a new study. ... 2007 to 2009 and focused on 13 patient safety ... foreign objects left in the body after procedures and ...
... 9, 2011) University of Minnesota researchers are using salmonella ... of U.S. residents each year to do what was ... Center researchers believe salmonella may be a valuable tool in ... such as the liver, spleen, and colon since that,s ...
Cached Medicine News:Health News:Lost DNA May Have Made Us More Human 2Health News:More reasons to be nice: It's less work for everyone 2Health News:Cerebral spinal fluid guides stem cell development in the brain 2Health News:Cerebral spinal fluid guides stem cell development in the brain 3Health News:Hospital Safety Varies Widely Nationwide: Report 2Health News:U of M researchers using salmonella to fight cancer 2
... catheter design and ergonomic handle for ... radiopaque Nitinol markers on the proximal ... enhance visibility. Corrugated ring design provides ... nested ring pattern minimizes stent shortening, ...
... and Response catheters comprise the world's ... for electrophysiology procedures. Their advanced catheter ... superior torque response with a soft, ... and French sizes, Supreme and Response ...
Coaxial Multicolor LIO Worlds first coaxial multicolor LIO provides precise laser delivery with repeatable outcomes, as well as maximum treatment options and physician safety....
Novus 3000 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
Medicine Products: